Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can enzyme pills beat the bloat? new study tests a simple fix for IBS sufferers

NCT ID NCT07465562

Symptom relief Sponsor: Liaquat University of Medical & Health Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study tested whether a dietary supplement containing digestive enzymes (Galactol®) could reduce bloating after meals in people with irritable bowel syndrome (IBS). 300 adults were randomly assigned to take the enzyme supplement plus a low-FODMAP diet, or just the diet alone, for 14 days. The main goal was to see if bloating intensity improved more with the supplement.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
digestive enzyme supplement (alpha-galactosidase, beta-galactosidase, prolyl-endopeptidase)
What this could lead to
If it works, this could offer a simple, over-the-counter option to ease bloating after meals for people with IBS.
What could go wrong
This is a small, short-term study (14 days) with no blinding, so results may be influenced by placebo effects. The supplement is tested alongside a special diet, so it's unclear if the supplement alone would help.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

300 people

The number who actually took part.

Started

Mar 2026

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older * Diagnosis of irritable bowel syndrome (IBS) according to Rome IV criteria * Presence of abdominal discomfort and bloating related to food ingestion * Ability and willingness to provide written informed consent Exclusion Criteria: * Age under 18 years * Antibiotic therapy within 30 days prior to enrollment * Presence of organic gastrointestinal diseases * History of digestive system resection * Pregnancy or breastfeeding * Drug use or alcohol abuse during the study period * Inability or refusal to provide written informed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Abdominal bloating are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

irritable bowel syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Abdominal bloating Irritable bowel syndrome

Contacts and locations

Locations

  • Casa di cura Quisisana

    Rome, Lazio, 00197, Italy

  • Nutribol

    Reggio Calabria, Calabria, 89124, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.